• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Duloxetine Contributing to a Successful Multimodal Treatment Program for Peripheral Femoral Neuropathy and Comorbid ‘Reactive Depression’ in an Adolescent
【24h】

Duloxetine Contributing to a Successful Multimodal Treatment Program for Peripheral Femoral Neuropathy and Comorbid ‘Reactive Depression’ in an Adolescent

机译：度洛西汀为青少年外周股神经病和合并症“反应性抑郁”的成功的多模式治疗方案做出了贡献

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the United States, duloxetine has been approved for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and fibromyalgia in the adult population. Data regarding the use of duloxetine in the pediatric population, however, are very limited. Femoral nerve injury is a rare complication of cardiac catheterization. In the case described, duloxetine contributed to a successful multimodal treatment program for peripheral neuropathic pain due to femoral neuropathy in an adolescent with ‘reactive depression’ and conversion symptoms. To the best of the authors’ knowledge, the present article is only the third such report on this dual use of duloxetine in children and adolescents, and the first report of such treatment following femoral neuropathy induced by cardiac catheterization.
机译：在美国，度洛西汀已被批准用于成人人群中的主要抑郁症，糖尿病性周围神经性疼痛和纤维肌痛的治疗。然而，有关度洛西汀在儿科人群中使用的数据非常有限。股神经损伤是心脏导管插入术的罕见并发症。在所描述的案例中，度洛西汀为成功治疗患有“反应性抑郁”和转换症状的青少年股神经病所致的周围神经性疼痛提供了成功的多模式治疗方案。据作者所知，本文仅是关于儿童和青少年双重使用度洛西汀的第三次此类报道，也是关于因心脏导管插入术引起股神经病变后进行此类治疗的第一篇报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号